Eloxatin®, Elplat®, Dacotin®, Dacplat®

A major advance in the history of cancer treatment

Oxaliplatin is a diaminocyclohexane (DACH) platin. It is the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®, which has dramatically changed the prognosis of colorectal cancer. In 1996, prior to the introduction of oxaliplatin, the standard of care for colorectal cancer was 5-fluorouracil (5-FU). Combination of oxaliplatin with 5-FU and leucovorin (FOLFOX) allowed to more than double the survival of patients with metastatic disease.

In 2000’s approval of oxaliplatin in adjuvant settings has significantly increased the number of patients cured. It is a worldwide standard treatment in metastatic colorectal cancer.

Debiopharm-Triptorelin-Elplat and Eloxatin

In short

Combination of oxaliplatin with 5-FU and leucovorin (FOLFOX) allowed to more than double the survival of patients with metastatic disease.

It is a worldwide gold standard treatment in
metastatic & adjuvant colorectal cancer
metastatic & adjuvant pancreatic cancer

Overview of the products

Indications

Metastatic colorectal cancer
Adjuvant setting in colorectal cancer
Pancreatic cancer in USA and in Japan
Liver cancer in China

Product Characteristics

3 dosages: 50mg – 100mg – 200mg
IV infusion
Freeze-dried and solution formulations

Debiopharm Value Added

Identification of the first clinical indication (mCRC)
Clinical development leading to the first file submission registration in France

Optimization of the efficacy-safety profile

Commercial map

Sanofi

United Arab Emirates
Albania
Austria
Australia
Bosnia and Herzegovina
Barbados
Bangladesh
Belgium
Bulgaria
Bermuda
Brazil
Bahamas, The
Botswana
Canada
Switzerland
Chile
Cameroon
China
Colombia
Costa Rica
Germany
Dominican Republic
Ecuador
Egypt
Spain
France
Greece
Guatemala
Hong Kong
Honduras
Croatia
Indonesia
Ireland
Israel
Iraq
Iran
Italy
Jordan
Kenya
South Korea
Kuwait
Cayman Islands (UK)
Lebanon
Luxembourg
Morocco
Moldova
Macedonia
Mauritius
Mexico
Malaysia
Namibia
Nigeria
Nicaragua
Oman
Panama
Peru
Philippines
Pakistan
Puerto Rico
Portugal
Romania
Russia
Saudi Arabia
Singapore
El Salvador
Chad
Thailand
Turkey
Trinidad and Tobago
Taiwan
Ukraine
United States
Venezuela
Vietnam
South Africa
Zimbabwe

More info

Yakult Honsha Co., Ltd

Japan

More info

Dr. Reddy's Laboratories

India

More info

Press Releases

October 24, 2023

Transfer of Marketing Authorization of Anticancer Drug Elplat® to Takata Pharmaceutical

Read more
March 10, 2017

Debiopharm International SA Appeals to the Supreme Court regarding Towa Pharmaceutical Co., Ltd. case

Read more
February 21, 2017

Debiopharm International SA Appeals to the Supreme Court regarding Nippon Kayaku Co., Ltd. case

Read more

All Press Releases

News

August 22, 2018

Increased Overall Survival (OS) of patients with pancreatic cancer: results of a Phase III study of adjuvant mFOLFIRINOX presented at…

Read more
June 10, 2015

Information letter – Yakult, our partner in Japan, announced the approval of Elplat in Gastric Cancer

Read more

All News

Selected publications

February 10, 2015

Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer

Read more
June 1, 2007

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer

Read more
April 20, 2007

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer

Read more

All Publications